AD/PD 2023 | Cell- and gene-therapy landscape in Parkinson’s disease

Emma Lane, PhD, Cardiff University in Cardiff, UK, shares an overview of current investigations into cell- and gene-based therapies for the treatment of Parkinson’s disease (PD). The current research landscape in this area is particularly exciting, with numerous trials taking off in the realm of cell therapy. Numerous induced pluripotent stem cell (iPSC) and human embryonic stem cell-derived products are being studied. It is hoped that collectively, these early trials will begin to demonstrate the safety and efficacy of cell-based approaches for treating PD. In addition to cell therapy, gene therapy approaches are also being explored in the management of PD. Researchers are investigating various methods, such as growth factor therapy or improving symptomatic relief through gene-based interventions. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.